A recent study published in The Journal of Clinical Investigation found that a combination of nicotinamide (NAM) and pyridoxine (PN) can effectively support muscle stem cells (MuSCs) and reverse age-associated muscle decline. This natural therapy activates key signaling pathways crucial for MuSC proliferation and differentiation, enhancing muscle growth and repair.
By Hugo Francisco de SouzaReviewed by Susha Cheriyedath, M.Sc.Dec 18 2024 How nicotinamide and pyridoxine offer a groundbreaking, safe solution to counter muscle loss and strengthen recovery in aging populations.
The natural aging process was found to reduce circulating NAM and PN levels, highlighting these FDA-approved nutrients as promising solutions for addressing age-related muscle degeneration. Interestingly, NAM and PN levels were directly associated with muscle mass and gait speed in a cohort of older adults, emphasizing their potential clinical significance.Background Skeletal muscles display a surprising amount of plasticity, dynamically adapting to exercise, injury, and disuse.
Pathway-Specific Benefits: Nicotinamide enhances β-catenin signaling, while pyridoxine activates the AKT pathway and energy metabolism, providing complementary mechanisms to optimize muscle stem cell function. The study methodology included imaging , screening , and molecular and biochemical assays to evaluate identified supplement performance under differing ages and concentrations. Statistical analyses included 2-tailed Student’s t-tests and Analysis of Variance for between-group computations. Since males and females are historically known to differ in their age-related muscle function decline rate, hMP assays were carried out on both male and female donor cells.
Since both differentiation and proliferation are required to achieve desired results, these assays suggest that combination therapies comprising both NAM and PN are required for optimal outcomes. Comparisons between old and young mice revealed that the circulating levels of NAM and PN declined with age, corresponding almost perfectly with observed declines in MuSC function.
Aging Muscle Loss Regenerative Medicine Nicotinamide Pyridoxine
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Draw magic shapes to create heroes in this combination of tower defense and factory-builderJon Bolding is a games writer and critic with an extensive background in strategy games. When he's not on his PC, he can be found playing every tabletop game under the sun.
Read more »
Temozolomide and radiation combination improves survival in low-grade glioma patientsBoth radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.
Read more »
Novel combination of surgery and embolization reduces recurrence of subdural hematomasA novel combination of surgery and embolization used to treat subdural hematomas, bleeding between the brain and its protective membrane due to trauma, reduces the risk of follow-up surgeries, according to researchers at Weill Cornell Medicine and University at Buffalo.
Read more »
Man Joins Groundbreaking Cancer Research Study After Childhood Pancreatitis StrugglesAdam Eshborn, a 51-year-old father of two from Catterall, joined the EUROPAC cancer research study due to his history of pancreatitis and the hereditary nature of the condition. He hopes his participation will contribute to earlier detection and improved survival rates for pancreatic cancer, a disease with one of the lowest survival rates among all cancers.
Read more »
Novel drug combination shows promise for CLL treatmentA novel, fixed-duration drug combination -; consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug -; shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD,...
Read more »
Promising combination therapy could improve liver cancer outcomesDan G. Duda, DMD, PhD, of the Edwin L.
Read more »